ArticleFrontiers in oncology2025
Differential diagnosis of benign and malignant vertebral compression fractures based on CT radiomics model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to develop a CT radiomics-based predictive model integrating clinical characteristics to distinguish benign and malignant vertebral compression fractures (VCFs). Methods: We retrospectively analyzed 208 patients with VCFs treated at our institution between January 2020 and November 2024. Patients were randomly divided into a training cohort (n = 145) and a validation cohort (n = 63). CT images were obtained, and three-dimensional lesion regions were manually segmented. A total of 1,316 radiomics features were extracted. Dimensionality reduction was performed using least absolute shrinkage and selection operator (LASSO) regression analysis and 5-fold cross-validation to identify key features. Univariate and multivariate analyses were used for identifying independent clinical predictors. Three models were constructed: a clinical model, a radiomics model, and a combined clinical-radiomics model. Model performance was evaluated using area under the receiver operating characteristic (ROC) curve (AUC), accuracy (ACC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), and negative predictive value (NPV). Predictive efficacy and clinical utility were further assessed via ROC curves, calibration plots, and decision curve analysis (DCA), along with clinical impact curves (CIC) and net reduction curves. The Delong test was used for statistical comparisons among different models, and a nomogram was developed to facilitate the visualization of the optimal model. Results: Carbohydrate antigen 125 (CA125) and posterior vertebral involvement were identified as independent clinical predictors. The combined model achieved the highest AUC value of 0.846 in the validation cohort, followed by the radiomics model (0.842), and the clinical model (0.640). Calibration curves and DCA confirmed its superior predictive accuracy and clinical benefit. Conclusions: The CT-based clinical-radiomics model demonstrated robust performance in differentiating benign from malignant VCFs and holds promise for guiding individualized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.